3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
7
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
3
Urologic Neoplasms
2
Neoplasm Metastasis
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Peripheral Nervous System Diseases
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Adenocarcinoma of the Bladder
1
Interventions
Nivolumab
22
Specimen Handling
17
pembrolizumab
13
cabozantinib
13
Magnetic Resonance Spectroscopy
13
belzutifan
12
Ipilimumab
12
lenvatinib
7
Axitinib
7
CTLA-4 Antigen
6
Biopsy
6
atezolizumab
4
Sunitinib
4
tivozanib
3
Surveys and Questionnaires
3
Immunoglobulin G
3
Everolimus
3
Disulfides
3
relatlimab
2
pazopanib
2
palbociclib
2
aldesleukin
2
Watchful Waiting
2
Standard of Care
2
Radiosurgery
2
Practice Guidelines as Topic
2
Nephrectomy
2
Bevacizumab
2
zimberelimab
1
ulixertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
enfortumab vedotin
×
30 days
×
Clear all
No trials found.